KZR Kezar Life Sciences Inc.

2.88
-0.06  -2%
Previous Close 2.94
Open 2.98
Price To Book 0.64
Market Cap 55,127,938
Shares 19,141,645
Volume 65,868
Short Ratio
Av. Daily Volume 130,563
Stock charts supplied by TradingView

NewsSee all news

  1. Kezar Life Sciences Enhances Clinical Expertise with the Appointment of Elizabeth Garner, MD, MPH to its Board of Directors

    SOUTH SAN FRANCISCO, Calif., Dec. 19, 2019 (GLOBE NEWSWIRE) -- Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing novel small molecule therapeutics to treat unmet

  2. Kezar Life Sciences Highlights Therapeutic Potential of Protein Secretion Inhibitors at the 61st American Society of Hematology Annual Meeting

    SOUTH SAN FRANCISCO, Calif., Dec. 09, 2019 (GLOBE NEWSWIRE) -- Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing novel small molecule therapeutics to treat unmet

  3. Kezar Life Sciences to Present at the Piper Jaffray 31st Annual Healthcare Conference

    SOUTH SAN FRANCISCO, Calif., Nov. 27, 2019 (GLOBE NEWSWIRE) -- Kezar Life Sciences, Inc. (NASDAQ:KZR), a clinical-stage biotechnology company discovering and developing novel small molecule therapeutics to treat unmet

  4. Kezar Life Sciences to Present at Upcoming Investor Conferences

    SOUTH SAN FRANCISCO, Calif., Nov. 14, 2019 (GLOBE NEWSWIRE) -- Kezar Life Sciences, Inc. (NASDAQ:KZR), a clinical-stage biotechnology company discovering and developing novel small molecule therapeutics to treat unmet

  5. Kezar Announces Promising New Data with KZR-616 at the American College of Rheumatology Annual Meeting

    Step-up dose titration lowered GI side effects while maintaining clinical activityMajority of patients completing 13 weeks of treatment demonstrated significant improvement on at least 2 measures of disease

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 2 interim analysis 1H 2021 with final data 2H 2021.
KZR-616
Lupus
Phase 1 initiation announced March 6, 2019.
KZR-616
Healthy volunteers
Phase 2 interim analysis 4Q 2020 with final data due mid-2021.
KZR-616
Autoimmune hemolytic anemia (AIHA) and immune thrombocytopenia (ITP)
Phase 2 data due 2H 2021.
KZR-616
Dermatomyositis and polymyositis

Latest News

  1. Kezar Life Sciences Enhances Clinical Expertise with the Appointment of Elizabeth Garner, MD, MPH to its Board of Directors

    SOUTH SAN FRANCISCO, Calif., Dec. 19, 2019 (GLOBE NEWSWIRE) -- Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing novel small molecule therapeutics to treat unmet

  2. Kezar Life Sciences Highlights Therapeutic Potential of Protein Secretion Inhibitors at the 61st American Society of Hematology Annual Meeting

    SOUTH SAN FRANCISCO, Calif., Dec. 09, 2019 (GLOBE NEWSWIRE) -- Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing novel small molecule therapeutics to treat unmet

  3. Kezar Life Sciences to Present at the Piper Jaffray 31st Annual Healthcare Conference

    SOUTH SAN FRANCISCO, Calif., Nov. 27, 2019 (GLOBE NEWSWIRE) -- Kezar Life Sciences, Inc. (NASDAQ:KZR), a clinical-stage biotechnology company discovering and developing novel small molecule therapeutics to treat unmet

  4. Kezar Life Sciences to Present at Upcoming Investor Conferences

    SOUTH SAN FRANCISCO, Calif., Nov. 14, 2019 (GLOBE NEWSWIRE) -- Kezar Life Sciences, Inc. (NASDAQ:KZR), a clinical-stage biotechnology company discovering and developing novel small molecule therapeutics to treat unmet

  5. Kezar Announces Promising New Data with KZR-616 at the American College of Rheumatology Annual Meeting

    Step-up dose titration lowered GI side effects while maintaining clinical activityMajority of patients completing 13 weeks of treatment demonstrated significant improvement on at least 2 measures of disease

  6. Kezar Life Sciences to Host Conference Call and Webcast during the American College of Rheumatology Annual Meeting to Discuss Updated Results with KZR-616

    SOUTH SAN FRANCISCO, Calif., Nov. 08, 2019 (GLOBE NEWSWIRE) -- Kezar Life Sciences, Inc. (NASDAQ:KZR), a clinical-stage biotechnology company discovering and developing novel small molecule therapeutics to treat unmet

  7. Kezar Life Sciences Reports Third Quarter 2019 Financial Results and Provides Business Update

    Additional data from the ongoing Phase 1b portion of the MISSION study to be presented at the 2019 ACR/ARP Meeting in Atlanta, GAPhase 2 MISSION, PRESIDIO, and MARINA trials with KZR-616 are progressingKZR-261 nominated

  8. Kezar Life Sciences Announces Presentations of Four Abstracts at the 2019 ACR/ARP Annual Meeting

    SOUTH SAN FRANCISCO, Calif., Oct. 01, 2019 (GLOBE NEWSWIRE) -- Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing novel small molecule therapeutics to treat unmet

  9. Kezar Life Sciences to Present at the 2019 Cantor Global Healthcare Conference

    SOUTH SAN FRANCISCO, Calif., Sept. 27, 2019 (GLOBE NEWSWIRE) -- Kezar Life Sciences, Inc. (NASDAQ:KZR), a clinical-stage biotechnology company discovering and developing novel small molecule therapeutics to treat unmet

  10. Kezar Life Sciences Announces Presentations at Upcoming Investor Conferences

    SOUTH SAN FRANCISCO, Calif., Aug. 28, 2019 (GLOBE NEWSWIRE) -- Kezar Life Sciences, Inc. (NASDAQ:KZR), a clinical-stage biotechnology company discovering and developing novel small molecule therapeutics to treat unmet